SELLAS Life Sciences Group, Inc. Common Stock
Symbol: SLS (NASDAQ)
1.99
▲ (1.79%) 0.035
Company Description:
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Key Stats
- Today's Open: $2.01
- Today's High: $2.01
- Today's Low: $1.922
- Today's Volume: 23.37K
- Yesterday Close: $1.95
- Yesterday High: $1.96
- Yesterday Low: $1.85
- Yesterday Volume: 5.83M
- Last Min Volume: 11
- Last Min High: $1.985
- Last Min Low: $1.985
- Last Min VWAP: $1.985
Company Profile
- Name: SELLAS Life Sciences Group, Inc. Common Stock
- Website: https://www.sellaslifesciences.com
- Listed Date: 2008-03-12
- Location: NEW YORK, NY
- Market Status: Active
- CIK Number: 0001390478
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $238.72M
- Round Lot: 100
- Outstanding Shares: 124.98M
- Asset Type: CS
RECENT FILINGS FOR SLS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-17 | SCHEDULE 13G | View |
| 2025-10-10 | S-3 | View |
| 2025-10-03 | 8-K | View |
| 2025-09-11 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-12 | S-8 | View |
| 2025-08-12 | 8-K | View |
| 2025-08-12 | 10-Q | View |
| 2025-07-29 | SCHEDULE 13G | View |
| 2025-06-18 | 8-K | View |
| 2025-06-13 | 4 | View |
| 2025-06-10 | DEFA14A | View |
| 2025-06-06 | 8-K | View |
| 2025-06-02 | 4 | View |
| 2025-05-22 | 4 | View |
| 2025-05-15 | SCHEDULE 13G | View |
| 2025-05-13 | 8-K | View |
| 2025-05-13 | 10-Q | View |
| 2025-04-23 | ARS | View |
| 2025-04-23 | DEFA14A | View |
Latest News on SLS